Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

DNA damage and repair in leukocytes of melanoma patients exposed in vitro to cisplatin

Texto completo
Shimabukuro, Fernanda [1] ; Neto, Cyro F. [2] ; Sanches, Jr., Jose A. [2] ; Gattas, Gilka J. F. [1]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Sch Med, Dept Legal Med Eth & Occupat Hlth, Sao Paulo - Brazil
[2] Univ Sao Paulo, Sch Med, Dept Dermatol, Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Melanoma Research; v. 21, n. 2, p. 99-105, APR 2011.
Citações Web of Science: 5

Resistance to chemotherapeutic drugs can be an obstacle to a successful treatment of cancer patients in part associated with individual response and differences in the DNA repair system. The Comet assay is an informative test to investigate DNA damage and repair in cells in response to a variety of DNA-damaging agents, including chemotherapeutic drugs. The aim of this study was to assess leukocytes damage after in-vitro cisplatin treatment and DNA repair action using the Comet assay in 20 patients with melanoma and 20 cancer-free individuals. Leukocytes' DNA damage before and after cisplatin treatment, in three different concentrations, was analyzed. The DNA repair capability was investigated after 1-5 h of in-vitro cells growing without cisplatin. The Comet score of the patients' basal DNA damage was higher than that observed in controls, but the difference was not statistically significant (P=0.85). Although both groups had similar Comet scores to all cisplatin concentrations tested and the DNA repair times, the basal DNA damage (P < 0.001) and cisplatin damages (P < 0.005) were statistically lower than the different repair times investigated. Considering the progressive increase in the Comet score due to repair time, the negative results here observed could be associated with the reduced cell culture incubation that should be better evaluated. Considering the mutagenic action of cisplatin on tumor cells and the importance of individual DNA repair mechanisms in the chemotherapeutic melanoma treatment, the peripheral leukocytes could be particularly useful as a tool for DNA repair response identified by the Comet assay. Melanoma Res 21:99-105 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams \& Wilkins. (AU)

Processo FAPESP: 06/52041-9 - Polimorfismos geneticos em pacientes com melanoma maligno.
Beneficiário:Gilka Jorge Figaro Gattas
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 07/51699-3 - Avaliacao in vitro da cisplatina, em linfocitos de pacientes com melanoma maligno, por meio de testes citogeneticos.
Beneficiário:Fernanda Shimabukuro
Linha de fomento: Bolsas no Brasil - Mestrado